$1.220
-0.057 (-4.69%)收盤時
MXCT 資訊
MXCT 事件
MaxCyte Reports Q2 Revenue of $7.27M, Beating Expectations
Reports Q2 revenue $7.27M, consensus $6.47M. "We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in processing assembly sales," said Maher Masoud, President and CEO of MaxCyte. "A significant development for MaxCyte was the recent signing of our first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech that we believe will unlock meaningful new opportunities for MaxCyte. Separately, our SPL portfolio remains a key driver of long-term value as evident by growing commercial royalty revenue and the advancement of a significant number of SPL programs through the clinic. Lastly, our goal has been to return to revenue growth while reducing our net losses. In the first half of 2026, we delivered a meaningful reduction in net loss and expect to benefit further as we continue to execute against our plan and return to revenue growth."
MaxCyte Enters Technology License Partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides Genentech with access to MaxCyte's ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering. The capabilities across MaxCyte platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery to cGMP manufacturing.
MaxCyte Expects $136 Million Cash by End of 2026
The company said, "MaxCyte expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for the share repurchase program."
MaxCyte Q1 Revenue $9.65M, Exceeds Expectations
Reports Q1 revenue $9.65M, consensus $7.3M. "We are pleased with our performance in the first quarter, and remain confident in our full year guidance," said Maher Masoud, President and CEO of MaxCyte. "Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely well positioned in the cell & gene therapy industry, with leading technology and an efficient cost structure. Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase. This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives, including the recent launch of ExPERT DTx and the integration of SeQure Dx. We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders."
MaxCyte Q4 Revenue at $7.3M, Below Consensus
Reports Q4 revenue $7.3M, consensus $9.16M. "Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base. Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte's position in the growing cell and gene therapy market for the long term," said Maher Masoud, president and CEO of MaxCyte.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。